People · Operator
Named in public records as an officer, director or promoter · active 2018–2020 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Vir Biotechnology, Inc. | — | Biotechnology | Series D+ | $348.4M | $1.3B | 2018 |
| Syros Pharmaceuticals, Inc. | — | Biotechnology | Series D+ | $296.1M | $2.6B | 2018 |
Philip Sharp at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Philip Sharp on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Nelsen | 2 | 22 |
| Vicki Sato | 2 | 6 |
| Kristina Burow | 1 | 16 |
| Amir Nashat | 1 | 14 |
| Srinivas Akkaraju | 1 | 10 |
| Robert More | 1 | 7 |
| Douglas Cole | 1 | 5 |
| Noubar B Afeyan | 1 | 5 |
| Stephane Bancel | 1 | 4 |
| George Scangos | 1 | 4 |
| Saira Ramasastry | 1 | 4 |
| Jorge Conde | 1 | 4 |
| Thomas Daniel | 1 | 4 |
| James E. Bradner | 1 | 3 |
| Timothy C. Tyson | 1 | 3 |
| Peter Wirth | 1 | 3 |
| Dipchand Nishar | 1 | 3 |
| Robert Perez | 1 | 3 |
| Robert E. Nelsen | 1 | 3 |
| Mark Alles | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.